JP2023550035A5 - - Google Patents

Info

Publication number
JP2023550035A5
JP2023550035A5 JP2023528148A JP2023528148A JP2023550035A5 JP 2023550035 A5 JP2023550035 A5 JP 2023550035A5 JP 2023528148 A JP2023528148 A JP 2023528148A JP 2023528148 A JP2023528148 A JP 2023528148A JP 2023550035 A5 JP2023550035 A5 JP 2023550035A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
inhibitor
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550035A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058775 external-priority patent/WO2022103834A1/en
Publication of JP2023550035A publication Critical patent/JP2023550035A/ja
Publication of JP2023550035A5 publication Critical patent/JP2023550035A5/ja
Pending legal-status Critical Current

Links

JP2023528148A 2020-11-11 2021-11-10 がん治療におけるmetap2阻害剤及びcdk4/6阻害剤の組み合わせ Pending JP2023550035A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112217P 2020-11-11 2020-11-11
US63/112,217 2020-11-11
US202163166060P 2021-03-25 2021-03-25
US63/166,060 2021-03-25
PCT/US2021/058775 WO2022103834A1 (en) 2020-11-11 2021-11-10 Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023550035A JP2023550035A (ja) 2023-11-30
JP2023550035A5 true JP2023550035A5 (cg-RX-API-DMAC7.html) 2024-11-12

Family

ID=78821168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528148A Pending JP2023550035A (ja) 2020-11-11 2021-11-10 がん治療におけるmetap2阻害剤及びcdk4/6阻害剤の組み合わせ

Country Status (8)

Country Link
US (1) US20230404963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4243807A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023550035A (cg-RX-API-DMAC7.html)
KR (1) KR20230117574A (cg-RX-API-DMAC7.html)
AU (1) AU2021378944A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198173A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005501A (cg-RX-API-DMAC7.html)
WO (1) WO2022103834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
EP4568706A1 (en) * 2022-08-10 2025-06-18 Syndevrx, Inc. Metap2 inhibitors for the treatment of pulmonary fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20130137831A1 (en) * 2010-05-25 2013-05-30 John S. Petersen Optimized drug conjugates
AU2017206718B2 (en) * 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
WO2019070755A1 (en) * 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US11612577B2 (en) * 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof
WO2023178255A1 (en) * 2022-03-16 2023-09-21 Syndevrx, Inc. Combinations comprising metap2 inhibitors for the treatment of cancer

Similar Documents

Publication Publication Date Title
BE1011980A5 (fr) Traitement du cancer avec des epothilones.
JP2002504511A5 (cg-RX-API-DMAC7.html)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
CN1339966A (zh) 治疗高血压的药物
JP2021523169A (ja) ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2021534160A5 (cg-RX-API-DMAC7.html)
JP6928000B2 (ja) 化学療法の改善
RU2002113659A (ru) Способ и композиции для перорального введения таксанов больным людям
JP2024517309A (ja) マルチキナーゼ阻害剤の医薬組成物および使用
ES2312978T3 (es) Potenciador del efecto antitumoral y agente antitumoral.
JP2007504259A (ja) エポチロンでの癌処置
JP2024538719A5 (cg-RX-API-DMAC7.html)
EP2117539B1 (en) A method of administering an antitumor compound
JP5570429B2 (ja) デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法
JP2025509613A5 (cg-RX-API-DMAC7.html)
JP7001834B6 (ja) 血管破壊剤およびタキサン化合物を含む癌の予防または治療用の組成物
JP2021533107A (ja) 癌を治療するための併用療法
TWI813694B (zh) 抗腫瘤劑及腫瘤治療方法
WO1996011681A1 (en) Preventive and remedy for diarrhea
JP2025541662A (ja) カピバセルチブ及びベネトクラクスの治療用組み合わせ
WO2023050297A1 (zh) 一种局部药物组合物、应用及试剂盒
NL8000332A (nl) Werkwijze voor het bereiden van een geneesmiddel dat een benzoc 1,6 naftyridine bevat.
JP2024544082A (ja) 三重陰性乳がんの予防または治療用薬学的組成物
JP2007530567A (ja) エポチロン及びカルボプラチンを用いる併用療法